The importance of HER2 has been well documented in breast cancer, where HER2 testing is a standard approach for identifying patients who may benefit from HER2-targeted agents such as lapatinib and trastuzumab therapy in metastatic and adjuvant settings [32,33]. This evidence concerns the gene ERBB2 and breast carcinoma.